{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.10","upperLimit":"4.02","value":"4.00"},{"groupId":"OG001","lowerLimit":"2.05","upperLimit":"5.73","value":"4.00"},{"groupId":"OG003","lowerLimit":"2.00","upperLimit":"6.08","value":"4.00"},{"groupId":"OG004","lowerLimit":"2.23","upperLimit":"6.37","value":"4.00"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"13"},{"groupId":"OG004","value":"12"}],"units":"Participants"}],"description":"Tmax is the time to reach Cmax.","dispersionType":"Full Range","groups":[{"description":"Participants received cobimetinib (on Day 1-21) plus venetoclax (on Day 1-28) at escalated doses, in 28-day cycles, to identify the dose level with acceptable safety.","id":"OG000","title":"Safety Run-In: Cobimetinib + Venetoclax"},{"description":"Participants received cobimetinib (on Day 1-21) plus venetoclax (on Day 1-28) at escalated doses and atezolizumab (on Day 1 and Day 15) at a fixed dose of 840 mg IV, in 28-day cycles, to identify the dose level with acceptable safety.","id":"OG001","title":"Safety Run-In: Cobimetinib + Venetoclax + Atezolizumab"},{"description":"Participants received the standard single-agent cobimetinib dose of 60 milligrams (mg) (3 tablets of 20 mg each) orally (PO) daily on Days 1-21 of each 28-day cycle until disease progression. Upon progression, participants were allowed to receive treatment with cobimetinib and atezolizumab at the recommended Phase II dose of cobimetinib 60 mg PO on Days 1-21 plus atezolizumab intravenous (IV) infusion at a fixed dose of 840 mg on Day 1 and Day 15 of each 28-day cycle. Treatment continued until disease progression, unacceptable toxicity, death, participant or physician decision to withdraw, or pregnancy, whichever occurred first.","id":"OG002","title":"A: Cobimetinib"},{"description":"Participants received cobimetinib PO daily on Days 1-21 of each 28-day cycle plus venetoclax PO daily on Days 1-28 of each 28-day cycle, at the dose level identified in the safety run-in phase. Treatment continued until disease progression, unacceptable toxicity, death, participant or physician decision to withdraw, or pregnancy, whichever occurred first.","id":"OG003","title":"B: Cobimetinib + Venetoclax"},{"description":"Participants received cobimetinib PO daily on Days 1-21 of each 28-day cycle plus venetoclax PO daily on Days 1-28 of each 28-day cycle, at the dose level identified in the safety run-in phase plus atezolizumab IV infusion at a fixed dose of 840 mg on Day 1 and Day 15 of each 28-day cycle. Treatment continued until disease progression, unacceptable toxicity, death, participant or physician decision to withdraw, or pregnancy, whichever occurred first.","id":"OG004","title":"C: Cobimetinib + Venetoclax + Atezolizumab"}],"paramType":"MEDIAN","populationDescription":"The PK population included participants from Arms A, B, and C who received at least one dose of study medication and for whom at least one evaluable PK sample was collected.","reportingStatus":"POSTED","timeFrame":"Pre-dose (within 1 hr), 2, 4, 6 hrs post-dose on Day 15 of Cycle 1 (cycle length: 28 days)","title":"Time to Reach Cmax (Tmax) of Cobimetinib","type":"SECONDARY","unitOfMeasure":"hr"}